Maria R. Baer
YOU?
Author Swipe
View article: American Society of Hematology 2025 guidelines for treating newly diagnosed acute myeloid leukemia in older adults
American Society of Hematology 2025 guidelines for treating newly diagnosed acute myeloid leukemia in older adults Open
Older adults with acute myeloid leukemia (AML) represent a cancer population in whom disease-based risk factors, comorbidities, patient goals, and treatment risks and benefits influence treatment recommendations. These evidence-based guide…
View article: Venetoclax (VEN) and azacitidine (AZA) with gilteritinib (GILT) in patients with newly diagnosed (ND) FLT3mut+ Acute Myeloid Leukemia (AML) ineligible for intensive induction chemotherapy (chemo): Interim results from the phase 1/2 VICEROY study
Venetoclax (VEN) and azacitidine (AZA) with gilteritinib (GILT) in patients with newly diagnosed (ND) FLT3mut+ Acute Myeloid Leukemia (AML) ineligible for intensive induction chemotherapy (chemo): Interim results from the phase 1/2 VICEROY study Open
VEN/AZA is the standard frontline treatment for adults with ND AML (including FLT3mut+ disease) ineligible for intensive induction chemo due to older age or comorbidities. Complete remission (CR; 38.1%) and 12-month overall survival (OS; 5…
View article: Results of the APG2575AU101 Study of lisaftoclax (APG-2575) combined with azacitidine (AZA) in patients with newly diagnosed (ND) or prior venetoclax–exposed myeloid malignancies
Results of the APG2575AU101 Study of lisaftoclax (APG-2575) combined with azacitidine (AZA) in patients with newly diagnosed (ND) or prior venetoclax–exposed myeloid malignancies Open
Introduction Acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) have poor prognoses. Venetoclax plus hypomethylating agent AZA is approved for certain patients with AML, but most have resistance or intolerance, warranting add…
View article: Prognostic and Therapeutic Implications of <i>BRAF</i> Mutations in Acute Myeloid Leukemia
Prognostic and Therapeutic Implications of <i>BRAF</i> Mutations in Acute Myeloid Leukemia Open
Mutations in the RAS/MAPK signaling pathway are recurrent in acute myeloid leukemia (AML), primarily involving NRAS and KRAS . In contrast, mutations in the gene encoding an effector protein, BRAF, occur at relatively lower frequencies in …
View article: Use of Emergency Severity Index 2 reduces time to first analgesia in sickle cell disease vaso-occlusive crisis
Use of Emergency Severity Index 2 reduces time to first analgesia in sickle cell disease vaso-occlusive crisis Open
Guidelines from the National Heart, Lung, and Blood Institute recommend assigning an Emergency Severity Index (ESI) acuity level 2 to patients with sickle cell disease (SCD) presenting to the emergency department (ED) with vaso-occlusive c…
View article: Ziftomenib in Relapsed or Refractory <i>NPM1</i> -Mutated AML
Ziftomenib in Relapsed or Refractory <i>NPM1</i> -Mutated AML Open
PURPOSE Ziftomenib—a potent, highly selective, oral menin inhibitor—was well tolerated and demonstrated encouraging clinical activity as monotherapy for relapsed/refractory NPM1 -mutated ( NPM1 -m) and KMT2A -rearranged AML in the KOMET-00…
View article: Impact of clinical response and treatment tolerability on HRQoL in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia patients treated with ponatinib or imatinib
Impact of clinical response and treatment tolerability on HRQoL in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia patients treated with ponatinib or imatinib Open
In the phase 3 PhALLCON trial (NCT03589326), ponatinib demonstrated superior efficacy, patient-reported treatment tolerability, and health-related quality of life (HRQoL) compared to imatinib in adults with newly diagnosed Philadelphia chr…
View article: Supplementary Figure S4 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant <i>TP53</i> and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years
Supplementary Figure S4 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant <i>TP53</i> and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years Open
p-H2AX as a pharmacodynamic biomarker for TP-0903. Spectral flow cytometry was performed to assess p-H2AX using peripheral blood collected at day 1 (i.e., baseline) and day 10, and change from screening was calculated for patients that ach…
View article: Supplementary Table S5 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant <i>TP53</i> and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years
Supplementary Table S5 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant <i>TP53</i> and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years Open
Treatment Completion and Reason Off Treatment
View article: Supplementary Table S6 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant <i>TP53</i> and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years
Supplementary Table S6 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant <i>TP53</i> and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years Open
TP-0903 and metabolite pharmacokinetic parameters on days 1 and 10 of course 1
View article: Supplementary Table S2 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant <i>TP53</i> and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years
Supplementary Table S2 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant <i>TP53</i> and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years Open
Dose Escalation Table
View article: Supplementary Figure S2 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant <i>TP53</i> and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years
Supplementary Figure S2 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant <i>TP53</i> and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years Open
Sequencing data. Serial sequencing versus response.
View article: Supplementary Table S1 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant <i>TP53</i> and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years
Supplementary Table S1 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant <i>TP53</i> and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years Open
Inclusion and Exclusion Criteria
View article: Supplementary Table S7 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant <i>TP53</i> and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years
Supplementary Table S7 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant <i>TP53</i> and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years Open
Research Resource Identifiers (RRID)
View article: Supplementary Figure S3 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant <i>TP53</i> and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years
Supplementary Figure S3 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant <i>TP53</i> and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years Open
Pharmacokinetic exposure versus toxicity/response. (A) Steady-state plasma levels of TP-0903 parent drug in non-responders and responders (CR, CRh, CRi, MLFS). Percent decrease in (B) absolute neutrophil count (ANC) or (C) platelets in pat…
View article: Supplementary Table S3 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant <i>TP53</i> and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years
Supplementary Table S3 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant <i>TP53</i> and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years Open
Representativeness of Study Participants
View article: Supplementary Table S4 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant <i>TP53</i> and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years
Supplementary Table S4 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant <i>TP53</i> and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years Open
All-Cause Adverse Events
View article: Supplementary Methods from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant <i>TP53</i> and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years
Supplementary Methods from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant <i>TP53</i> and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years Open
Supplementary Methods
View article: Supplementary Figure S1 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant <i>TP53</i> and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years
Supplementary Figure S1 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant <i>TP53</i> and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years Open
Consort diagram
View article: Olutasidenib alone or combined with azacitidine in patients with mutant <i>IDH1</i> myelodysplastic syndrome
Olutasidenib alone or combined with azacitidine in patients with mutant <i>IDH1</i> myelodysplastic syndrome Open
Olutasidenib, a potent, selective, oral small-molecule inhibitor of mutant isocitrate dehydrogenase 1 (mIDH1), is US Food and Drug Administration approved for mIDH1 relapsed/refractory (R/R) acute myeloid leukemia based on results from the…
View article: Supplementary Table S7 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant <i>TP53</i> and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years
Supplementary Table S7 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant <i>TP53</i> and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years Open
Research Resource Identifiers (RRID)
View article: Supplementary Figure S2 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant <i>TP53</i> and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years
Supplementary Figure S2 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant <i>TP53</i> and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years Open
Sequencing data. Serial sequencing versus response.
View article: Figure 3 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant <i>TP53</i> and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years
Figure 3 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant <i>TP53</i> and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years Open
TP53 VAF. A,TP53 VAF by best response. TP53 VAF over time in patients that achieved CR/CRh/CRi/MLFS (B) without relapse on study or (C) with relapse while on study. Patients who received 37 mg TP-0903 are represented by closed symbols, whe…
View article: Figure 1 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant <i>TP53</i> and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years
Figure 1 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant <i>TP53</i> and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years Open
OS and duration of response. Patients were treated according to the (A) study schema. B, OS and (C) duration of response among patients who achieved CR + CRh + CRi. The median OS for all patients (n = 27) was 7.6 months (95% CI, 3.3–13.4) …
View article: Supplementary Figure S3 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant <i>TP53</i> and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years
Supplementary Figure S3 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant <i>TP53</i> and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years Open
Pharmacokinetic exposure versus toxicity/response. (A) Steady-state plasma levels of TP-0903 parent drug in non-responders and responders (CR, CRh, CRi, MLFS). Percent decrease in (B) absolute neutrophil count (ANC) or (C) platelets in pat…
View article: Supplementary Table S1 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant <i>TP53</i> and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years
Supplementary Table S1 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant <i>TP53</i> and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years Open
Inclusion and Exclusion Criteria
View article: Data from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant <i>TP53</i> and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years
Data from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant <i>TP53</i> and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years Open
Purpose:Older patients who have acute myeloid leukemia (AML) with mutant TP53 and/or complex karyotype have a dismal prognosis and lack treatment options. Having previously demonstrated that TP-0903, a multikinase inhibitor, has compelling…
View article: Table 3 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant <i>TP53</i> and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years
Table 3 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant <i>TP53</i> and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years Open
Treatment response, response duration, and OS table
View article: Supplementary Figure S1 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant <i>TP53</i> and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years
Supplementary Figure S1 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant <i>TP53</i> and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years Open
Consort diagram
View article: Supplementary Figure S4 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant <i>TP53</i> and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years
Supplementary Figure S4 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant <i>TP53</i> and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years Open
p-H2AX as a pharmacodynamic biomarker for TP-0903. Spectral flow cytometry was performed to assess p-H2AX using peripheral blood collected at day 1 (i.e., baseline) and day 10, and change from screening was calculated for patients that ach…